Regulatory Roundup: Device Ban Supported; Obesity Device Panel; Eyelid Weights
This article was originally published in The Gray Sheet
Executive Summary
FDA neuro panel supports FDA’s proposed ban of electrical stimulation devices used for “aversive conditioning.” The agency has officially scheduled an advisory panel meeting to consider EnteroMedics’s PMA for the implantable Maestro Rechargeable System as a weight-loss tool in obese patients. More regulatory news.
You may also be interested in...
FDA’s Upcoming Drug/Diagnostic Co-Development Guidance Could Quickly Become Outdated
Tests that look for many markers at a time “may completely change” the paradigm for companion diagnostics, CDRH’s Elizabeth Mansfield says.
Big Pharma CEOs Suggest Policy Changes As They Return To Beijing
Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.
For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion
After postponing planned November advisory committees’ meeting to have time to review more information it requested from sponsor HRA Pharma, FDA sets meeting for 9-10 May. Expanding meeting from one day to a day and a half should allow considering all views and questions about contraceptives.